title: Libraries of 2β-(N-substituted piperazino)-5α-androstane-3α, 17β-diols: chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes.
abstract: Libraries of steroid derivatives with two levels of molecular diversity were prepared to optimize the antiproliferative activity on leukemia HL-60 cells by first varying the amino acid (AA) at R(1) (libraries A, B, C, and D: with 45, 45, 20, and 20 members, respectively) and, subsequently, the capping group at R(2) (library E: 168 members). The screening of these aminosteroids revealed interesting structure-activity relationships. In library A, the compounds bearing a tetrahydroisoquinolone residue as the first element of diversity showed potent cytotoxicity, principally when isovaleric or cyclohexyl acetic acid was used as a capping group (>40% of cell growth inhibition at 1 μM). In library B, the phenylalanine (Phe) derivatives bearing a cyano group induced a higher growth inhibition than the other Phe derivatives. The screening of library C indicated the increase of hydrophobicity of proline (Pro) seems to preserve the cytotoxic effect achieved by the lead compound. However, the synthesis of structural Pro variants (library D) clearly shows weaker activities when compared to L-Pro building blocks. Finally, by incorporating some of the most active AA of libraries A-D in library E, we observed that the amide coupling functionality gave stronger cytotoxic activity compared to the corresponding sulfonamides or benzylamines. Six of the most active amide derivatives (E-37P, E-41P, E-42P, E-46P, E-48F, and E-12T) were selected and IC(50) determined on HL-60 cells as well as on normal human lymphocytes. Among this series of new anticancer agents, good to high selectivity indices (SI = IC(50) (lymphocytes)/IC(50) (HL-60 cells) = 5 - 55) were obtained.
authors.affiliation: Laboratory of Medicinal Chemistry, Endocrinology and Genomic Unit, CHUQ-(CHUL) Research Center, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
authors.forename: Jenny
authors.initials: J
authors.lastname: Roy
authors.forename: René
authors.initials: R
authors.lastname: Maltais
authors.forename: Hajer
authors.initials: H
authors.lastname: Jegham
authors.forename: Donald
authors.initials: D
authors.lastname: Poirier
mesh_terms: D015113:Androstane-3,17-diol / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D054852:Small Molecule Libraries / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*
chemical_list: D054852:Small Molecule Libraries; D015113:Androstane-3,17-diol
references.citation: J Comb Chem. 2000 Nov-Dec;2(6):604-14
references.pmid: 11126290
references.citation: J Comb Chem. 2007 May-Jun;9(3):347-58
references.pmid: 17441773
references.citation: J Clin Invest. 2000 Jan;105(1):3-7
references.pmid: 10619854
references.citation: Bioorg Med Chem. 2001 Dec;9(12):3101-11
references.pmid: 11711285
references.citation: Life Sci. 2006 Sep 27;79(18):1692-701
references.pmid: 16824549
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Leuk Lymphoma. 2007 Mar;48(3):605-15
references.pmid: 17454606
references.citation: J Comb Chem. 2003 Jul-Aug;5(4):429-40
references.pmid: 12857111
references.citation: Leukemia. 2004 Aug;18(8):1332-9
references.pmid: 15190258
references.citation: Mini Rev Med Chem. 2006 Jan;6(1):37-52
references.pmid: 16457631
references.citation: ChemMedChem. 2006 Nov;1(11):1249-59
references.pmid: 16986200
references.citation: J Comb Chem. 2004 Jul-Aug;6(4):443-56
references.pmid: 15244402
references.citation: Bioorg Med Chem. 2008 May 1;16(9):5062-77
references.pmid: 18375126
references.citation: Leuk Res. 1999 Apr;23(4):369-72
references.pmid: 10229323
references.citation: J Med Chem. 1997 May 23;40(11):1668-81
references.pmid: 9171876
references.citation: Mol Divers. 2005;9(1-3):67-79
references.pmid: 15789554
references.citation: Clin Ther. 2009;31 Pt 2:2349-70
references.pmid: 20110045
references.citation: Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15
references.pmid: 18056932